Revaree Plus for vaginal dryness in breast cancer survivors
Part of Cancer, Skin clinical trials.
This trial tests a vaginal insert called Revaree Plus to see if it helps breast cancer survivors who have vaginal dryness or pain from hormone therapy. It may be a good option if you are on an aromatase inhibitor or tamoxifen and have discomfort.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older with stage 0–3 hormone-receptor positive breast cancer.
- You have finished your main cancer treatments (surgery, chemo, radiation) or are on maintenance therapy, and your cancer is currently not active.
- You are currently taking an aromatase inhibitor (like anastrozole, letrozole, or exemestane) or tamoxifen.
- You are bothered by vaginal dryness, pain with intercourse, or discomfort during a pelvic exam.
- You have not had any other cancer (except non-melanoma skin cancer).
- You are willing to stop using any vaginal estrogen products or nonhormonal moisturizers for 4 weeks before starting the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a gentle radiofrequency treatment can help breast cancer patients with vaginal dryness that hasn't improved with standard moisturizers. It aims to improve comfort and quality of life.
This study examines vaginal dryness and discomfort—common side effects of breast cancer treatment—in women who've survived the disease. Researchers want to understand how often this happens and how much it affects daily life, which may help doctors better support survivors.
This trial tests a non-surgical radiofrequency treatment, combined with pelvic floor exercises, to help with vaginal dryness and other menopause symptoms in breast cancer survivors. It may be an option if you are free of cancer and have bothersome vaginal dryness.
This trial tests a medication called bupropion to see if it can help increase sex drive in women who have a reduced interest in sex due to hormone-blocking therapy for breast cancer. The goal is to make it easier for women to stick with their hormone treatment.
This Phase 1/2 study tests how well a new treatment combination (VS-6766, abemaciclib, and fulvestrant) works for metastatic or hard-to-remove breast cancer that is hormone-driven (ER/PR positive) and HER2 negative. It is mainly designed to find the safest dose and then see whether it can control the cancer after it has progressed on certain prior medicines.
This study looks at ways to prevent and treat sexual discomfort in people with hormone-receptor positive breast cancer. It targets women who are not having current vaginal dryness or pain related to lower estrogen, and may help protect sexual comfort during cancer-related hormone treatment.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.